Amgen - Medical Professionals

Contact Reimbursement Connection®

All you need to get your questions answered.

Call Reimbursement Connection®. Let us help you cut through the confusion so that you can focus on your patients—call Reimbursement Connection® directly at 1-800-272-9376. Every attempt will be made to ensure a reimbursement expert is available for your call. If all experts are answering other calls, please leave a message. We will use our best efforts to return your call within 1 business day.

For prompt service, please be prepared with the following:

Physician Information

Name, address, telephone and fax numbers, and tax ID number

Patient Information

Patient's written authorization to disclose patient identifiable and medical information (required)
Name, address, telephone number, ID number, and social security number
Insurance policy number or group coverage number
Diagnosis and treatment regimen

Insurer Information

Name, address, and telephone number of patient's insurer
Reason for rejecting or underpaying the claim, if applicable
Copy of the claim, if applicable

Get answers to clinical and product-related questions You may also contact Amgen directly to get answers to your clinical and product-related questions:

For clinical questions

Medical Information Connection™: 1-800-77-AMGEN

For product ordering and general inquiries

Customer Service: 1-800-28-AMGEN

Neulasta® Indication and Important Product Safety Information

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebo-treated patients (31% vs 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain.

footer